Global Breast Lesion Localization Methods Market is expected to reach USD 1,367.61 million by 2025 from USD 544.56 million in 2017, at a CAGR of 12.3% in the forecast period 2018 to 2025. The new market report contains data for historic years 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.
The global breast lesion localization methods market is highly concentrated to a few big players and rest to local players who cater to domestic markets only. ARGON MEDICAL dominated the breast cancer lesion localization methods market accounting for a highest market share in 2017, followed by Cook Group and C. R. Bard, Inc. Other players in this market include are CP Medical, Inc., Cianna Medical, STERYLAB S.r.l., SOMATEX Medical Technologies GmbH, Elucent Medical, Tsunami S.r.l., M.D.L. srl and Biomedical Srl among others.
ARGON MEDICAL, incepted in 1972 and headquartered at Texas, U.S. The company is engaged in the production of stainless steel guidewires for critical care procedures, interventional cardiology interventional radiology, and vascular surgery.. It is one of the pioneered companies in thrombus management, dialysis, vascular tools, drainage catheters and bone and soft tissue biopsy needles.
It has 800 employees globally. It has its global networks through direct sales representatives and distributors in the United States and internationally. It operates as a subsidiary of ACI Medical Devices, Inc.
Founded in 1963 and headquarter at Bloomington, Indiana, Cook Group is a privately held company which is focusing in the manufacturing of medical devices. The company operates through three main divisions, namely, Cook Services Cook Medical, and Cook Properties. The all three divisions are made up of several subsidiary companies. These three segments are operated by various subsidiaries present globally. The first products of company included catheters, needles, and wire guides. Cook Medical offers more than 16,000 products across 13 hospital service lines, and provides its services to over 135 countries..
C. R. Bard, Inc.:
Founded in 1907 and headquartered at Murray Hill, New Jersey, U.S. C. R. Bard, Inc. is engaged in the development, manufacturing and marketing of medical technologies. The company operates through four business segments: vascular, urology, oncology and surgical specialties. The vascular segment offers a wide range of products for endovascular and grafts includes biopsy devices, peripheral angioplasty catheters, drug-coated PTA balloons, vena cava filters, peripheral vascular stents and stent grafts, dialysis access grafts and peripheral vascular grafts. The urology segment of the company offers various products pertaining to basic drainage, continence, urological specialty, catheter stabilization, targeted temperature and management’s products. The oncology segment of the company offers various devices including implantable ports, peripherally inserted central catheters (PICCs) and vascular access ultrasounds. The key products included in the surgical specialties are soft tissue repair, performance irrigation and bio-surgical products.
Global Breast Lesion Localization Methods Market – Industry Trends and Forecast to 2029
North America Breast Lesion Localization Methods Market - Industry Trends and Forecast to 2029
Europe Breast Lesion Localization Methods Market – Industry Trends and Forecast to 2029
Asia-Pacific Breast Lesion Localization Methods Market - Industry Trends and Forecast to 2029